VCYT Stock Price Today (July 2026) — Veracyte, Inc. Analysis & Key Metrics 2026-07-17
Veracyte, Inc. (VCYT) is trading at $59.13, down 0.15% today (as of July 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $49.10 (-17.0% upside).
- Volatility remains elevated (39.81% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (21.50% YoY) alongside significant competitive pressures.
VCYT Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
Veracyte, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $4.29B
P/E Ratio
Forward P/E: 31.71
Revenue Growth
Year over Year
Analyst Target
+-17.0% upside potential
Key Investor Questions About VCYT
What investors need to know before buying
Based on current market data, VCYT presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 60.50)
- Fundamentals say: Caution warranted (high leverage concerns)
VCYT's growth trajectory depends on its ability to expand within the Diagnostics & Research sector while managing margin pressures.
- Future growth will depend on performance in core Diagnostics & Research operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for VCYT investors include debt exposure and competitive dynamics in the Diagnostics & Research industry.
- $39.33M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Diagnostics & Research.
52-Week Trading Range
Over the past year, VCYT stock traded between $22.61 and $60.91—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 39.81% annualized volatility and β=1.31, the stock exhibits high sensitivity to market moves—making VCYT suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
RxSight (RXST) Surges 6.1%: Is This an Indication of Further Gains?
RxSight (RXST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
All You Need to Know About Veracyte (VCYT) Rating Upgrade to Strong Buy
Veracyte (VCYT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
A Veracyte Insider Sold 24,000 Company Shares for $1.1 Million. Here's a Deeper Look at the Transaction.
This genomic diagnostics company saw a notable insider sale, as shares have surged over 70% in the past year.
Veracyte Stock Surges 117% in a Year: What's Driving the Rally?
VCYT's 117% stock surge is driven by durable growth plans, Afirma demand, TrueMRD progress, international IVD efforts and a debt-free balance sheet.
What to Know About This $197,000 Veracyte Insider Sale After a 120% Stock Rally
This genomics diagnostics specialist, up over 120% in a year, reported a notable insider sale amid ongoing scheduled dispositions.
This Top Stock Has Surged. CEO Explains Key To Veracyte's Success.
Veracyte opened its doors with a simple theory: Not all cancer patients need surgery or chemotherapy. Now, Veracyte stock is on a run.
Dow Jones Futures: Techs Rebound, SpaceX Rises Despite Trump's Iran Threat; Warsh's Fed Debut Due
Tech futures are rising modestly despite President Trump's threat to resume bombing Iran. Fed chief Kevin Warsh's comments loom.
Dow Jones Futures Rise Before Warsh's Fed Debut; SpaceX Keeps Rising, Four Stocks In Buy Areas
The Dow Jones hit a new high and SpaceX kept rising. But chips and most AI stocks fell. Fed chief Kevin Warsh's comments will be in focus Wednesday.
This Top Stock Has Surged. CEO Explains Key To Veracyte's Success.
Veracyte opened its doors with a simple theory: Not all cancer patients need surgery or chemotherapy. Now, Veracyte stock is on a run.
Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Frequently Asked Questions
Common investor questions about Veracyte, Inc.
Veracyte, Inc. (VCYT) is currently trading at $59.13. The RSI (14-day) is at 60.5, indicating neutral territory. Wall Street analysts have a consensus "Hold" recommendation. The mean analyst price target of $49.10 implies 17.0% downside from current levels. Volatility is moderate at 39.8% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Veracyte, Inc. (VCYT): The trailing P/E ratio is 54.75, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 31.71, lower than the trailing P/E, suggesting analysts expect earnings improvement. Price-to-Book is 3.58. Price-to-Sales is 8.71. Valuation should be compared to Diagnostics & Research industry peers for context, as different sectors trade at different multiples.
Based on 10 analysts covering VCYT, the consensus price target is $49.10. This represents a 17.0% downside from the current price of $59.13. The range spans from a low target of $37.00 to a high target of $57.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "Hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Veracyte, Inc. (VCYT) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Veracyte, Inc. (VCYT) investors include: 1. Moderate volatility (39.8% annualized)—price swings are notable. 2. Elevated short interest (12.6% of float) suggests significant bearish sentiment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Diagnostics & Research sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Veracyte, Inc.'s (VCYT) current debt and financial health profile: Total debt stands at $39.33M. The debt-to-equity ratio is 2.93, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 9.30, indicating strong short-term liquidity. The quick ratio is 8.72. The company holds $439.06M in cash and equivalents. Free cash flow is positive at $104.51M, providing a cushion for debt servicing and shareholder returns.